Results 111 to 120 of about 194,896 (265)

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

open access: yesThe Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi   +21 more
wiley   +1 more source

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia   +4 more
wiley   +1 more source

Trends in the incidence of cancers of the breast and female genital tract in Harare, Zimbabwe 1990–2019

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Cancers of the breast and female genital tract represent more than half of all cancers in women in sub‐Saharan Africa. Here, the authors assessed incidence trends in a female population living in urban sub‐Saharan Africa based on the Zimbabwe National Cancer Registry in Harare over a 30‐year period.
Eric Chokunonga   +7 more
wiley   +1 more source

Risk stratification and anal cancer screening in immunocompetent women with genital HPV: Value of multicentric HSIL and performance of HPV‐based screening

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Anal squamous cell carcinoma (ASCC) incidence is increasing, with most cases occurring in immunocompetent women. ASCC risk is linked in particular to genital human papillomavirus (HPV) infection and HPV‐associated high‐grade squamous intraepithelial lesions (HSILs).
Isabel Matas   +13 more
wiley   +1 more source

Nationwide Study on the Cervical Cancer Screening Pathway in Estonia

open access: yesInternational Journal of Cancer, EarlyView.
Cervical cancer remains a significant burden despite being preventable, largely due to inadequate screening participation and poor follow‐up of high‐risk women. Here, the authors investigated follow‐up rates among women who tested positive for high‐risk human papillomavirus (hr‐HPV) infection in primary screening in Estonia. Data show that more than 57
Aleksandra Šavrova   +6 more
wiley   +1 more source

Survival by Detection Pathway in Patients With Lung Cancer—A Nationwide Descriptive Epidemiological Study in Japan

open access: yesInternational Journal of Cancer, EarlyView.
Lung cancer is detected primarily through screening, incidental findings, or presentation with symptoms. In Japan, the impact of detection pathway on prognosis is poorly understood, limiting evaluation of screening effectiveness. The authors of the present study analyzed Japanese National Cancer Registry data, comparing clinical characteristics and net
Ryo Koto   +7 more
wiley   +1 more source

Iris metastasis from lung adenocarcinoma diagnosed solely through aqueous humor cytology: A case report. [PDF]

open access: yesAm J Ophthalmol Case Rep
Okubo A   +7 more
europepmc   +1 more source

The Predictive Value of the Tumor‐Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor‐Positive Breast Cancer

open access: yesInternational Journal of Cancer, EarlyView.
Neoadjuvant endocrine therapy (NET) can help prevent metastases and improve survival in patients with hormone receptor‐positive (HR+) breast cancer. Identifying which HR+ patients will benefit from NET, however, remains challenging. Here, in a patient cohort in the Netherlands, the authors evaluated tumor‐stroma ratio (TSR) and magnetic resonance ...
Layla Andour   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy